Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Halozyme Therapeutics Insider Sold Shares Worth $567,661, According to a Recent SEC Filing

Halozyme Therapeutics Insider Sold Shares Worth $567,661, According to a Recent SEC Filing

MT newswireMT newswire2026/10/02 20:42
04:42 PM EDT, 10/02/2026 (MT Newswires) -- Matthew L. Posard, Director, on October 01, 2026, sold 5,230 shares in Halozyme Therapeutics (HALO) for $567,661. Following the Form 4 filing with the SEC, Posard has control over a total of 53,609 common shares of the company, with 53,609 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000133/xslF345X05/wk-form4_1790973495.xml
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!